NASDAQ · Biotechnology · USD
VivoSim Labs, Inc. (VIVS) Stock Analysis
VivoSim Labs, Inc. (VIVS) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
VIVS Key Statistics
As of Oct 21, 2026Trading
- Open
- $0.16
- Previous Close
- $0.17
- Day's Range
- 0.16–0.18
- 52-Week Range
- 0.15–3.40
- Volume
- 1.86M
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 1.49
Valuation
- Market Cap
- $2.94M
- P/E Ratio
- unprofitable
- P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
- 26.21
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −4.47
Financials (FY)
- Revenue (FY)
- $131.00K−9.03%
- Net Income (FY)
- −$13.84M
- Shares Outstanding
- 16.59M
- 1-Year Return
- −92.95%
Dividend and dates
- Avg Volume
- 2.83M
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, VIVS closed at $0.18, −92.95% over 1 year.
VivoSim Labs, Inc. (VIVS) has a market capitalization of $2.94M.
In fiscal 2025, VIVS reported revenue of $131.00K.
VIVS Stock Return by Calendar Year
VivoSim Labs, Inc. (VIVS) 10-year return: what $10,000 became
- 1 year
- $10,000 $705
- −92.95%
- 5 years
- $10,000 $24
- −99.76%
- 10 years
- $10,000 $2
- −99.98%
If you had invested $10,000 in VivoSim Labs, Inc. (VIVS) 10 years ago, at the close on October 21, 2016, it would have been worth $2 at the close on October 21, 2026: −99.98% in total, −56.41% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −90.22% |
| 2025 | −67.21% |
| 2024 | −58.56% |
| 2023 | −21.28% |
| 2022 | −61.16% |
| 2021 | −70.49% |
| 2020 | +70.83% |
| 2019 | −62.50% |
| 2018 | −28.36% |
| 2017 | −60.47% |
| 2016 (partial year) | −29.52% |
As of October 21, 2026.
VIVS Revenue and Earnings by Fiscal Year
FY ends March| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $131.00K | −$13.84M | −10,567.2% |
| 2024 | $144.00K | −$2.49M | −1,727.8% |
| 2023 | $109.00K | −$14.67M | −13,459.6% |
| 2022 | $370.00K | −$17.26M | −4,664.6% |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $131.00K | $131.00K | −$11.49M | −$13.84M | −10,567.2% |
| 2024 | $144.00K | $139.00K | −$12.62M | −$2.49M | −1,727.8% |
| 2023 | $109.00K | $109.00K | −$15.09M | −$14.67M | −13,459.6% |
| 2022 | $370.00K | — | −$17.73M | −$17.26M | −4,664.6% |
Annual figures as reported, in the company's reporting currency. As of March 31, 2026.
VIVS Valuation vs Biotechnology Median
Median of 608 stocks| Metric | VIVS | Biotechnology median | vs median |
|---|---|---|---|
| P/S ratio | 26.21 | 13.30 | 97% above |
Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.
Recent News
VivoSim Labs To Extend Its Human Tissue Platform Beyond Toxicology With Efficacy Testing Services Built On NAMkind Disease Models Of The Liver And Intestine
BenzingaVivoSim Labs Celebrates Updated FDA Regulations Allowing Greater use of Non-Animal Testing Methods
YahooVivosim Labs Notes FDA's Direct Final Rule Clarifying That Non-Animal Methods Can Be Used Where Appropriate For Testing Safety Of Drugs And Biological Products For Human Use
BenzingaVivoSim Labs Unveils New NAMkind™ Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCs
YahooVivoSim Labs to Add Rat Liver Model to NAMkind Platform
YahooVivoSim Labs Plans To Develop Rat Liver Model To Complement Existing NAMkind Human Liver Platform And Expand Its Liver Toxicology Capabilities
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B